Side-by-side comparison of AI visibility scores, market position, and capabilities
Beta Bionics (Nasdaq: BBNX) makes the iLet Bionic Pancreas, the first autonomous closed-loop insulin delivery system; reported Q1 2026 revenue of $27.6M (+57% YoY) with 24,000+ active users.
Beta Bionics is a commercial-stage medical device company focused on transforming the management of insulin-requiring diabetes. Its flagship product is the iLet Bionic Pancreas, a device that automates insulin delivery using a proprietary adaptive algorithm that requires no carbohydrate counting, correction boluses, or manual basal rate programming from the user — the system learns from glucose readings and autonomously adjusts insulin delivery to maintain target glucose levels. The iLet is compatible with continuous glucose monitors including Dexcom G6, Dexcom G7, and FreeStyle Libre 3 Plus.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.